Mon, Apr 21, 2014, 6:45 AM EDT - U.S. Markets open in 2 hrs 45 mins

Recent

% | $
Quotes you view appear here for quick access.

ANI Pharmaceuticals, Inc. Message Board

  • forgecool forgecool Oct 27, 2009 10:48 PM Flag

    Let's just talk about the potential market for FSD!

    So the fact is 43% of females are diagnosed with Female Sexual Dysfunction of FSD and we have roughly about $2.5 billions market for estrogen and testosterone products and another $2 to $3 billion for FSD treatment potentially. Libigel is by far the only closest FDA-approved drug (Phrase III) in this class with the exception of non-FDA approved Intrinsa in the UK.

    Head up, women will like this drug. I rest my case!!!! As always do your homework, invest with your head not your heart.



    Here's some info on Intrinsa:

    "The medication Intrinsa which is the only Female Sexual Dysfunction prescription remedy available in the UK works by releasing very small amounts of testosterone into the bloodstream and has had good results with many women. Women going through menopause often suffer from low levels of testosterone which is normally associated with men but is necessary in smaller quantities in women not only for good sexual function but also for general well being"

    http://www.ukmedix.com/intrinsa/oestrogen_research_leads_to_new_findings4978.cfm

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • http://www.veracast.com/opco/healthcare09/main/doreg_fd.cfm

      excellent presentation

      common stock outstanding 53.3 million
      warrants 5.7 million
      options 3.0 million
      fully diluted shares 62.0 million

      news on cancer immunotherapies coming in a few months
      libigel partner/merger/licensing deal before drug application

    • Nord, I'd suggest you take some time, maybe a long time and figure out why women may want to benifit from Libigel after they go through their changes????? Think with the right head now.......Do you have script for the crap you force out of you head pocket?

      "Given the stunning popularity of treatments for sex-life enhancing therapies in men, and the differences between male and female psychology and physiology, what differences in degree of success should we expect in sex-life enhancing therapies in women?"

    • My question may have been poorly worded, a botched attempt at making light of a serious question with sexual implications. The gist of my question, all joking aside, is this...

      Given the stunning popularity of treatments for sex-life enhancing therapies in men, and the differences between male and female psychology and physiology, what differences in degree of success should we expect in sex-life enhancing therapies in women?

      Thats a fair question.

      @Jeff, ever beth's the white knight, maybe when you come back, you can leave the fk'in high horse.

    • easy everyone...I'm sure nord didn't mean anything by it. Besides, he's wrong anyway.

      How would this help a woman who is unattractive? Think about it...

      Unless BPAX is also selling beer goggles, it does no good.

      I'm with you jeff and beth, it's a horrible thing to go thru..I've seen it (both from cancer and early menopause).

      I think nord was just having a little fun..as we all should be following the CEGE fiasco. At least we have a good company here in BPAX.

    • Beth

      Its horrible what these women have to go through with dealing with breast cancer.......Yes Nord we need to "grow up"

      Your insensitivity in your commnents here is a mind fk that people like you really exist. Your coming back as a frog, if your lucky!

      Dope

    • Its a fair question. If you take exception to the wording of my question, well... grow up.

    • younger women with breast cancer face early menopause due to chemotherapy treatment.

    • "for a women, that is not so hot to trot anymore... how urgent is that? (I don't expect we'll get women of the "not so hot to trot affliction" to comment so easily, but worth the shot :)"

      Only a jackass would say something something like this. Its part of growing older for both men and women. Did you know that some women go through their changes late 30's early forties. go back to the cege board.......

    • This is a great thread, thank you all for posting. I got here by way of being a CEGE investor (fascinated with the prospect of the proverbial cure for cancer). Haven't really given much thought to where we landed (just that we landed somewhere), but the contents of this thread are really encouraging.

      Libigel is like 'fluff' medicine. Not a cure for a life threatening or debilitating disease, but something that conceivable (or at least promises to) enhance quality of life. Provided an affluent population, this could easily be a 'popular' product. Altogether very different from the proverbial cure for cancer, but potentially profitable non-the-less.

      Makes you think of the psyc difference between men and women with regard to their sexual capacity. For a man to not "get it up"... BIIIIIGGGG PRRROOOBBLLEEEMMM... !!!FIX AT ALL COST!!! BEEP BEEEP BEEEEP !!!... for a women, that is not so hot to trot anymore... how urgent is that? (I don't expect we'll get women of the "not so hot to trot affliction" to comment so easily, but worth the shot :)

      Anyways, cheers

    • Nonsense. There will be plenty of marketers to choose from once Libigel is FDA approved. 43% is a robust statistics, not to be taken lightly. Any big Pharma would jump on a drug that has such a large market potential. IMHO, Bpax is not in the radar of major institutional investors and that may be its only short term problem, which in a way is actually good for us to accumulate its shares at a fantastic discount. In the long haul, this drug's odd of finishing the race is significantly higher than a lot of other biopharm companies sharing its market cap range.

    • View More Messages
 
ANIP
25.55+0.76(+3.07%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.